GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Careers
  • Contact
  • Menu Menu

News Archive

GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology

02/26/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology. Read the full press release.

Read more

Biotech Showcase 2018

02/22/2018

David S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy. Watch the video.

Read more

GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences

02/12/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, […]

Read more

Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley

02/08/2018

I think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather […]

Read more

Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential

02/05/2018

GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and […]

Read more

GigaGen Announces New Office Space in South San Francisco

01/23/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art […]

Read more

GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin

01/16/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin […]

Read more

GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets

12/19/2017

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, […]

Read more

GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting

12/14/2017

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]

Read more

GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires

08/29/2017

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming […]

Read more

GigaGen closes $50M deal with Grifols

07/21/2017

GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

Read more

GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies

02/28/2017

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse […]

Read more

GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies

11/01/2016

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development […]

Read more

GigaGen CEO Dave Johnson on Biotech Nation Radio – Ep. 16-41

10/13/2016

Listen to Moira Gunn’s interview with Dave Johnson, PhD, CEO of GigaGen on “Creating a Synthetic Immune System” on Biotech Nation Radio.

Read more

GigaGen to Present on Copying and Mining Immune Systems for Drug Discovery at the LakePharma Protein Engineering Symposium

10/05/2016

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in […]

Read more

GigaGen and Cellular Therapeutics Ltd Sign Collaboration for Novel TCR Discovery Directly from Patient’s T cells

09/27/2016

GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the […]

Read more

GigaGen Wins Best E-Poster Award at ESID for Presentation of Preclinical Data for Recombinant Intravenous Immunoglobulin (IVIG)

09/23/2016

GigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain. For details of the […]

Read more

GigaGen Announces $1.5M NIH Grant Award for Development of Recombinant Intravenous Immunoglobulin

09/20/2016

GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute […]

Read more

GigaGen Announces Issue of US Patent for Polyclonal Antibody Production

09/13/2016

GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]

Read more

GigaGen Highlighted in Biospace.com Story

04/19/2016

GigaGen’s development of the world’s first synthetic immune system was covered recently in the Biospace.com story Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies.   According to the article, “The development of therapeutics that harness the body’s immune system has exploded in popularity among biotech companies with many investing heavily in research and […]

Read more
Page 4 of 512345

Latest Tweets

GigaGen Follow

Billions of immune cells in your bloodstream fight disease on a daily basis. GigaGen turns these cells into life-saving medical therapies.

gigageninc
GigaGen @gigageninc ·
21 Jun

Polyclonal #AntibodyTherapies contain a variety of antibody types and are ideal for diseases that comprise many targets. We’re developing the first #RecombinantPolyclonal antibody therapies for the treatment of infectious diseases. Learn more: https://bit.ly/38xUi5Z

Reply on Twitter 1539231952494116864 Retweet on Twitter 1539231952494116864 Like on Twitter 1539231952494116864 1 Twitter 1539231952494116864
GigaGen @gigageninc ·
14 Jun

On #WorldBloodDonorDay today, we thank all the blood and #plasma donors worldwide who help to provide a source of lifesaving therapies, including #antibody therapies for patients with #InfectiousDiseases.

Reply on Twitter 1536695417592758273 Retweet on Twitter 1536695417592758273 2 Like on Twitter 1536695417592758273 2 Twitter 1536695417592758273
GigaGen @gigageninc ·
7 Jun

This month, we’re proud to support @CancerResearch’s #CancerImmunotherapyMonth and contribute to developing safer and more effective #immunotherapies for patients in need. Learn about how you can support cancer immunotherapy research this month: https://bit.ly/3MHetgg

Reply on Twitter 1534218665415122944 Retweet on Twitter 1534218665415122944 Like on Twitter 1534218665415122944 Twitter 1534218665415122944
GigaGen @gigageninc ·
27 May

We’re advancing the first recombinant #polyclonal #antibody products to treat patients with #InfectiousDiseases and #immunodeficiencies. Learn more about our work and approach: https://bit.ly/3fTeXj1

Reply on Twitter 1530172179752570880 Retweet on Twitter 1530172179752570880 2 Like on Twitter 1530172179752570880 1 Twitter 1530172179752570880
GigaGen @gigageninc ·
19 May

We are happy to announce the publication of our latest peer-reviewed research article demonstrating the potential of our machine learning platform to improve antibody drug discovery and development. Learn more in our press release here: https://bit.ly/3MpERvb

Reply on Twitter 1527341245416165393 Retweet on Twitter 1527341245416165393 1 Like on Twitter 1527341245416165393 2 Twitter 1527341245416165393
©Copyright 2022 GigaGen. All Rights Reserved. | Privacy Policy | Terms | Disclaimer
  • Twitter
  • LinkedIn
Scroll to top